How biopharma companies can make the best choices

An Expert View from Leslie Orne, president and chief executive, Trinity Life Sciences.

The biopharma industry is intensely competitive, and companies must go to great lengths to gain any commercial edge. However, it is also an industry that sees more failure than success. Preclinical investigations run into dead ends. Clinical trials don’t meet their endpoints. Even drugs that make it to market often fail to generate substantial revenue. 

To complicate matters, the commercial environment is becoming increasingly constrained. The Inflation Reduction Act and other emerging revenue restraints are tightening margins across the industry. As a result, corporate efficiency is becoming an increasingly valuable competitive advantage.